A Hybrid Machine Learning and Network Analysis Approach Reveals Two Parkinson’s Disease Subtypes from 115 RNA-Seq Post-Mortem Brain Samples

Abstract

Precision medicine emphasizes fine-grained diagnostics, taking individual variability into account to enhance treatment effectiveness. Parkinson’s disease (PD) heterogeneity among individuals proves the existence of disease subtypes, so subgrouping patients is vital for better understanding disease mechanisms and designing precise treatment. The purpose of this study was to identify PD subtypes using RNA-Seq data in a combined pipeline including unsupervised machine learning, bioinformatics, and network analysis. Two hundred and ten post mortem brain RNA-Seq samples from PD (n = 115) and normal controls (NCs, n = 95) were obtained with systematic data retrieval following PRISMA statements and a fully data-driven clustering pipeline was performed to identify PD subtypes. Bioinformatics and network analyses were performed to characterize the disease mechanisms of the identified PD subtypes and to identify target genes for drug repurposing. Two PD clusters were identified and 42 DEGs were found (p adjusted ≤ 0.01). PD clusters had significantly different gene network structures (p < 0.0001) and phenotype-specific disease mechanisms, highlighting the differential involvement of the Wnt/β-catenin pathway regulating adult neurogenesis. NEUROD1 was identified as a key regulator of gene networks and ISX9 and PD98059 were identified as NEUROD1-interacting compounds with disease-modifying potential, reducing the effects of dopaminergic neurodegeneration. This hybrid data analysis approach could enable precision medicine applications by providing insights for the identification and characterization of pathological subtypes. This workflow has proven useful on PD brain RNA-Seq, but its application to other neurodegenerative diseases is encouraged.

WARE: Wet AMD Risk-Evaluation Tool as a Clinical Decision-Support System Integrating Genetic and Non-Genetic Factors

“…The role of biomedical research and innovation in the discovery and development of new protocols is essential to quickly and effectively respond to the different needs of patients and relatives. On this subject, the realization and implementation of molecular assays combined with computational analysis methods stand out as crucial to fulfil the demand for effective preventive, diagnostic, prognostic, and treatment strategies of disease conditions [ 1 , 2 ]. In this perspective, the design of new strategies and personalized medicine represent a powerful tool for preventing the establishment of disease conditions and promoting the preservation of health and quality of life.…”

Exploring the State of Machine Learning and Deep Learning in Medicine: A Survey of the Italian Research Community

“…Alzheimer's disease [35][36][37][38][39][40] Autism Spectrum Disorders [41,42] Brain Tumors [43][44][45] Breast Diabetes [73][74][75][76][77][78] Exposure to extremely low frequency waves [79,80] Glioblastoma [81,82] Heart Failure [83][84][85][86][87] Kidney Disease [88,89] Lung Cancer [90][91][92][93][94] Melanoma [95,96] Multiple Sclerosis [97][98][99] Parkinson's Disease [100][101][102][103][104][105][106][107] Prostate Cancer [108,109] Rectal Cancer [110]…”

Finding Group Gene Biomarkers by improved LRP algoirthm and Intersection Selection Idea

“…Gene sequencing is of great value in disease screening [4][5][6][7], mechanism research [19][20][21], drug discovery [8][9][10] and other fields. The traditional methods, such as bioinformatics [22][23][30][31] and machine learning [26][27][28], etc.…”